

Vangelis D Karalis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9579338/publications.pdf>

Version: 2024-02-01

77
papers

1,131
citations

448610

19
h-index

591227

27
g-index

78
all docs

78
docs citations

78
times ranked

1265
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. <i>American Journal of Medicine</i> , 2022, 135, 32-38.	0.6	41
2	Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination. <i>American Journal of Hematology</i> , 2022, 97, E3.	2.0	12
3	The Pharmacokinetics of Levetiracetam in Critically Ill Adult Patients: An Intensive Care Unit Clinical Study. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 1208.	1.3	1
4	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. <i>Biomedicines</i> , 2022, 10, 204.	1.4	7
5	Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in Greece. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	10
6	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.	1.4	21
7	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. <i>HemaSphere</i> , 2022, 6, e677.	1.2	17
8	Quantifying the effect of in-hospital antimicrobial use on the development of colistin-resistant <i>Acinetobacter baumannii</i> strains: a time series analysis. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, 66-71.	0.5	0
9	Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study. <i>Frontiers in Endocrinology</i> , 2022, 13, 840668.	1.5	15
10	On the Association between Gastrointestinal Symptoms and Extragastric Manifestations. <i>Gastroenterology Research and Practice</i> , 2022, 2022, 1-10.	0.7	0
11	Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations. <i>Xenobiotica</i> , 2021, 51, 127-138.	0.5	6
12	Association of Antibiotic Use with the Resistance Epidemiology of <i>Pseudomonas aeruginosa</i> in a Hospital Setting: A Four-Year Retrospective Time Series Analysis. <i>Scientia Pharmaceutica</i> , 2021, 89, 13.	0.7	5
13	Investigating the Impact of Gastric Emptying on Pharmacokinetic Parameters Using Delay Differential Equations and Principal Component Analysis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 451-458.	0.6	1
14	Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens. <i>Xenobiotica</i> , 2021, 51, 643-656.	0.5	19
15	Correlation between <i>Acinetobacter baumannii</i> Resistance and Hospital Use of Meropenem, Cefepime, and Ciprofloxacin: Time Series Analysis and Dynamic Regression Models. <i>Pathogens</i> , 2021, 10, 480.	1.2	9
16	Management of Acute Radiodermatitis in Non-Melanoma Skin Cancer Patients Using Electrospun Nanofibrous Patches Loaded with <i>Pinus halepensis</i> Bark Extract. <i>Cancers</i> , 2021, 13, 2596.	1.7	10
17	Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. <i>Osteoporosis International</i> , 2021, 32, 2313-2321.	1.3	0
18	Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?. <i>American Journal of Hematology</i> , 2021, 96, E321-E324.	2.0	17

#	ARTICLE	IF	CITATIONS
19	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. <i>Vaccines</i> , 2021, 9, 712.	2.1	25
20	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Cells</i> , 2021, 10, 1942.	1.8	38
21	3D-Printed Oral Dosage Forms: Mechanical Properties, Computational Approaches and Applications. <i>Pharmaceutics</i> , 2021, 13, 1401.	2.0	30
22	An In Vitro–In Vivo Simulation Approach for the Prediction of Bioequivalence. <i>Materials</i> , 2021, 14, 555.	1.3	5
23	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021, 11, 1077.	1.1	25
24	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Blood</i> , 2021, 138, 4202-4202.	0.6	0
25	Validation of population pharmacokinetic models: a comparison of internal and external validation approaches for hydrochlorothiazide. <i>Xenobiotica</i> , 2021, 51, 1372-1388.	0.5	1
26	Interplay between baroreflex sensitivity, obesity and related cardiometabolic risk factors (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 23, 67.	0.8	5
27	Do we need to adopt antifungal stewardship programmes?. <i>European Journal of Hospital Pharmacy</i> , 2020, 27, 14-18.	0.5	12
28	Modelling gastric emptying: A pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-174. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 193-202.	1.2	9
29	Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 153, 105498.	1.9	8
30	Probing the release of the chronobiotic hormone melatonin from hybrid calcium alginate hydrogel beads. <i>Acta Pharmaceutica</i> , 2020, 70, 527-538.	0.9	10
31	Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. <i>Xenobiotica</i> , 2020, 50, 1090-1100.	0.5	7
32	Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations. <i>Safety Science</i> , 2020, 129, 104842.	2.6	19
33	A retrospective study on the evaluation of the symptoms, medications and improvement of the quality of life of patients undergoing robotic surgery for gastroesophageal reflux disease. <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 174.	0.8	3
34	In Vivo Evaluation of the Anti-Inflammatory Activity of Electrospun Micro/Nanofibrous Patches Loaded with Pinus halepensis Bark Extract on Hairless Mice Skin. <i>Materials</i> , 2019, 12, 2596.	1.3	15
35	Hematocrit effect on dried blood spots in adults: a computational study and theoretical considerations. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2019, 79, 325-333.	0.6	19
36	Development of a joint population pharmacokinetic model of ezetimibe and its conjugated metabolite. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 128, 18-26.	1.9	8

#	ARTICLE	IF	CITATIONS
37	On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe. <i>Xenobiotica</i> , 2019, 49, 446-456.	0.5	7
38	On the pharmacokinetics of two inhaled budesonide/formoterol combinations in asthma patients using modeling approaches. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 48, 168-178.	1.1	10
39	Laparoscopic total extraperitoneal inguinal hernia repair. <i>Medicine (United States)</i> , 2018, 97, e13974.	0.4	8
40	4CPS-077â€¦Do we need to adopt antifungal stewardship programmes?. , 2018, , .		0
41	Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 407-419.	1.1	11
42	Paediatric Medicines: Regulatory and Scientific Issues. <i>Drug Research</i> , 2017, 67, 377-384.	0.7	3
43	In vitro Controlled Release from Solid Pharmaceutical Formulations of two new Adamantane Aminoethers with Antitubercular Activity (I).. <i>Drug Research</i> , 2017, 67, 447-450.	0.7	8
44	In vitro Controlled Release of two new Tuberculocidal Adamantane Aminoethers from Solid Pharmaceutical Formulations (II). <i>Drug Research</i> , 2017, 67, 653-660.	0.7	7
45	Modeling and Simulation in Bioequivalence. <i>Interdisciplinary Applied Mathematics</i> , 2016, , 227-254.	0.2	0
46	Ropivacaine, Interleukin-6 and Tumor Necrosis Factor Alpha Plasma Levels during Intermittent Epidural and Continuous Wound Infusion of Ropivacaine for Analgesia after Hysterectomy or Myomectomy: An Observational Study. <i>Pharmacology</i> , 2016, 98, 294-298.	0.9	2
47	Generic drugs- do they offer the same safety and efficacy as originator medicines? -perceptions and attitudes of final year pharmacy students in greece. <i>Value in Health</i> , 2016, 19, A461.	0.1	0
48	From Bioequivalence to Biosimilarity: The Rise of a Novel Regulatory Framework. <i>Drug Research</i> , 2016, 66, 1-6.	0.7	9
49	Bioequivalence studies in Europe before and after 2010. <i>Clinical Research and Regulatory Affairs</i> , 2015, 32, 9-21.	2.1	0
50	Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 80, 33-42.	1.9	20
51	Generic Products of Antiepileptic Drugs: A Perspective on Bioequivalence, Bioavailability, and Formulation Switches Using Monte Carlo Simulations. <i>CNS Drugs</i> , 2014, 28, 69-77.	2.7	21
52	A non-binary biopharmaceutical classification of drugs: The ABÎ“ system. <i>International Journal of Pharmaceutics</i> , 2014, 464, 85-90.	2.6	23
53	On the statistical model of the two-stage designs in bioequivalence assessment. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 66, 48-52.	1.2	11
54	Quantitative assessment of the switchability of generic products. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 476-483.	1.9	14

#	ARTICLE	IF	CITATIONS
55	The role of the upper sample size limit in two-stage bioequivalence designs. <i>International Journal of Pharmaceutics</i> , 2013, 456, 87-94.	2.6	6
56	Exploring the Relationships Between Scaled Bioequivalence Limits and Within-Subject Variability. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 297-301.	1.6	2
57	Keeping a Critical Eye on the Science and the Regulation of Oral Drug Absorption: A Review. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3018-3036.	1.6	28
58	An Insight into the Properties of a Two-Stage Design in Bioequivalence Studies. <i>Pharmaceutical Research</i> , 2013, 30, 1824-1835.	1.7	17
59	Safety and Pharmacokinetics of Oseltamivir for Prophylaxis of Neonates Exposed to Influenza H1N1. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 527-529.	1.1	20
60	Current regulatory approaches of bioequivalence testing. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 929-942.	1.5	16
61	Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA. <i>Pharmaceutical Research</i> , 2012, 29, 1066-1077.	1.7	60
62	Novel methods to assess bioequivalence. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 79-88.	1.5	8
63	On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 497-505.	1.9	20
64	Examining the Role of Metabolites in Bioequivalence Assessment. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2010, 13, 198.	0.9	14
65	Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: Focus on human exposure to drugs. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 38, 55-63.	1.9	7
66	Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability. <i>Pharmaceutical Research</i> , 2008, 25, 1956-1962.	1.7	53
67	Novel Scaled Bioequivalence Limits with Leveling-off Properties. <i>Pharmaceutical Research</i> , 2006, 23, 2657-2664.	1.7	27
68	Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 26, 54-61.	1.9	33
69	A Physiologically Based Approach for the Estimation of Recirculatory Parameters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 198-205.	1.3	13
70	Novel Scaled Average Bioequivalence Limits Based on GMR and Variability Considerations. <i>Pharmaceutical Research</i> , 2004, 21, 1933-1942.	1.7	32
71	Michaelis-Menten Kinetics under Spatially Constrained Conditions: Application to Mibefradil Pharmacokinetics. <i>Biophysical Journal</i> , 2004, 87, 1498-1506.	0.2	35
72	The heterogeneous course of drug transit through the body. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 140-146.	4.0	26

#	ARTICLE	IF	CITATIONS
73	Pharmacodynamic considerations in bioequivalence assessment: comparison of novel and existing metrics. <i>European Journal of Pharmaceutical Sciences</i> , 2003, 19, 45-56.	1.9	24
74	Quantitative structure–pharmacokinetic relationships for disposition parameters of cephalosporins. <i>European Journal of Pharmaceutical Sciences</i> , 2003, 20, 115-123.	1.9	30
75	Drug disposition viewed in terms of the fractal volume of distribution. <i>Pharmaceutical Research</i> , 2002, 19, 697-704.	1.7	19
76	Multivariate statistics of disposition pharmacokinetic parameters for structurally unrelated drugs used in therapeutics. <i>Pharmaceutical Research</i> , 2002, 19, 1827-1834.	1.7	18
77	Fractal volume of drug distribution: it scales proportionally to body mass. <i>Pharmaceutical Research</i> , 2001, 18, 1056-1060.	1.7	19